Alvameline

Alvameline

Alvameline (also known as LU 25-109) is a molecule that acts as a mixed muscarinic acetylcholine receptor agonist and M1 allosteric agonist. It was developed by Lundbeck for the treatment of Alzheimer's disease, but its development was discontinued after phase II clinical trials.

Chemistry

Alvameline is a quinuclidine derivative. It is chemically known as (3R,4R)-3-ethyl-4-((1-methyl-1H-imidazol-4-yl)methyl)dodecahydro-2H-pyrido[3,4-b][1,4]oxazin-2-one. Its molecular formula is C14H26N4O2.

Pharmacology

Alvameline has a high affinity for muscarinic acetylcholine receptors. It acts as a full agonist at the M1 and M2 subtypes, and as a partial agonist at the M3, M4, and M5 subtypes. The M1 allosteric agonism of Alvameline is thought to enhance its efficacy in the treatment of Alzheimer's disease.

Clinical Trials

Alvameline was tested in phase II clinical trials for the treatment of Alzheimer's disease. However, the development was discontinued due to lack of efficacy in improving cognitive function in patients.

See Also

• Muscarinic acetylcholine receptor
• Alzheimer's disease
• Clinical trial
• Lundbeck

References

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!